BAXDELA™ (delafloxacin) is FDA approved in the US for the treatment of serious skin infections

BAXDELA™ (delafloxacin) is FDA approved in the US for the treatment of serious skin infections known as acute bacterial skin and skin structure infections (ABSSSI).

For more information about Baxdela for treatment of ABSSSI, please visit

ChemSpider 2D Image | Delafloxacin | C18H12ClF3N4O4

Baxdela is an anionic fluoroquinolone antibiotic, a class currently used in one out of three hospital-treated infections. Baxdela has demonstrated in-vitro and clinical activity against Gram-positive and Gram-negative pathogens, including activity against MRSA (methicillin-resistant Staphylococcus aureus), a major cause of hospital-treated skin infections. Baxdela provides for convenient administration with both intravenous and oral forms.

Baxdela is indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following:

Gram-positive organisms.

Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates), Staphylococcus haemolyticus, Staphylococcus lugdunensis, Streptococcus agalactiae, Streptococcus anginosus Group (including Streptococcus anginosus, Streptococcus intermedius, and Streptococcus constellatus), Streptococcus pyogenes, and Enterococcus faecalis;

Gram-negative organisms.

Escherichia coli, Enterobacter cloacae, Klebsiella pneumoniae, and Pseudomonas aeruginosa.


Tendinitis and Tendon Rupture, Peripheral Neuropathy, Central Nervous System Effects, Exacerbation of Myasthenia Gravis, Hypersensitivity Reactions, and Clostridium difficile-Associated Diarrhea, and Development of Drug-Resistant Bacteria.


Baxdela is contraindicated in patients with known hypersensitivity to delafloxacin or any of the fluoroquinolone class of antibacterial drugs, or any of the components of Baxdela.


Most common adverse reactions (incidence ≥ 2%) are nausea, diarrhea, headache, transaminase elevations and vomiting.

 Development Status for New Indications

 Melinta is conducting a Phase 3 clinical program in serious community-acquired bacterial pneumonia (CABP) and may develop additional indications such as complicated urinary tract infections (cUTI). Quinolones are considered a standard of care in the treatment of CABP and cUTI. Baxdela is not currently FDA approved for the treatment of CABP or cUTI.

 Melinta has received Qualified Infectious Disease Product (QIDP) designation from the U.S. FDA for the ABSSSI and CABP indications, which provides Baxdela with priority review and extends its market exclusivity period by an additional 5 years beyond the 5 years provided by Hatch-Waxman legislation. Melinta has partnerships in place for delafloxacin outside the US.

20 June, 2017

0
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote